#China #World AIDS Day #Xi'an #Tianlong #Blood Screening

Enhancing Blood Safety on World AIDS Day 2025

On December 1, 2025, World AIDS Day became a significant event for Tianlong Science and Technology as the company reinforced its commitment to improving global transfusion safety. Offering a groundbreaking fully integrated nucleic acid blood screening solution, Tianlong aims to enhance early detection of infections in blood transfusion processes, an approach that is critical in the fight against transfusion-transmitted HIV.

A Commitment to Safety

Transfusion safety is fundamental in curtailing the risks associated with blood transfusions, especially regarding transferable infections. Tianlong's newly launched platform combines high automation and high-sensitivity nucleic acid testing (NAT) reagents, enabling laboratories to detect low-viral-load infections earlier than ever before. This proactive approach is vital in reducing the transmission potential of diseases such as HIV and others, ultimately safeguarding the health of patients depending on safe blood donations.

Integrating Automation into Blood Screening

At the heart of the new solution lies the Aurora PANA X6 Fully Automated Nucleic Acid Extraction System, designed specifically for blood centers and large-scale screening initiatives. Such a system, in conjunction with the Gentier 96 Real-time PCR System, paves the way for the comprehensive automation of the blood screening process. The technology allows for a streamlined sample-in, result-out workflow, integrating essential steps such as:

• - Original tube loading
• - Barcode identification
• - Automated capping and decapping
• - Direct sample pooling
• - Nucleic acid extraction
• - PCR setup and amplification

This holistic automation not only minimizes manual input but also reduces contamination risks, fundamentally enhancing the safety and efficiency of laboratory operations.

Meeting High-Volume Demands

The Aurora PANA X6 is capable of processing up to 576 samples per run and 1,152 samples per day—considerably high throughput necessary for extensive blood screening tasks. Additionally, the system’s direct pooling capabilities into deep-well plates eliminate the need for multiple collection tubes, streamlining operations while promoting consistency in contamination-controlled environments.

Focus on High-Sensitivity Testing

To bolster its automated screening capabilities, Tianlong integrates KHB's high-sensitivity NAT reagents. These reagents are engineered to detect various infections including HBV, HCV, HIV-1, and HIV-2, even when the viral loads are exceptionally low. The utilization of qualitative real-time PCR in a unified format, combining extraction and amplification, empowers laboratories to promptly identify infections during critical window periods—further refining the overall safety of the blood supply.

A Global Call for Enhanced Safety

As Li Ming, Tianlong’s CEO, articulated on World AIDS Day, “Every safe transfusion represents a promise of protection for another human life.” His sentiment echoes the company's overarching mission: to provide laboratories with sophisticated solutions that not only enhance the safety and accuracy of blood testing but also contribute significantly to global health efforts against HIV transmission.

About Tianlong

Founded in 1997, Tianlong Science and Technology stands as a vanguard in genetic testing and molecular diagnostics. By collaborating with its partner, Shanghai Kehua Bio-engineering Co., Ltd. (KHB), Tianlong has developed a comprehensive portfolio comprising various technology platforms, including immunodiagnostics, biochemistry, and molecular diagnostics. These innovations span across critical sectors such as clinical diagnostics, blood centers, and food safety.

For further insights into their initiatives, exploration of the Tianlong website and their social media platforms on LinkedIn, Facebook, and Twitter is highly encouraged.